Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).
Griesinger F, Sebastian M, Brueckl WM, Hummel HD, Jaeschke B, Kern J, Wesseler C, Jänicke M, Fleitz A, Zacharias S, Hipper A, Groth A, Weichert W, Dörfel S, Petersen V, Schröder J, Wilke J, Eberhardt WEE, Thomas M; CRISP Registry Group. Griesinger F, et al. JTO Clin Res Rep. 2023 Dec 25;5(4):100626. doi: 10.1016/j.jtocrr.2023.100626. eCollection 2024 Apr. JTO Clin Res Rep. 2023. PMID: 38586301 Free PMC article.
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
Gosney JR, Paz-Ares L, Jänne P, Kerr KM, Leighl NB, Lozano MD, Malapelle U, Mok T, Sheffield BS, Tufman A, Wistuba II, Peters S. Gosney JR, et al. Among authors: tufman a. ESMO Open. 2023 Aug;8(4):101587. doi: 10.1016/j.esmoop.2023.101587. Epub 2023 Jun 23. ESMO Open. 2023. PMID: 37356358 Free PMC article.
Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors.
Mönch S, Heimer MM, Winkelmann M, Guertler A, Schlaak M, Tufman A, Ben Khaled N, de Toni E, Westphalen CB, von Bergwelt-Baildon M, Dinkel J, Kazmierczak PM, Ingrisch M, Mansour N, Unterrainer M, Heinzerling L, Ricke J, Kunz WG. Mönch S, et al. Among authors: tufman a. Cancer Imaging. 2023 Jun 8;23(1):58. doi: 10.1186/s40644-023-00580-9. Cancer Imaging. 2023. PMID: 37291665 Free PMC article.
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
Hofstetter K, Taugner J, Käsmann L, Mansoorian S, Flörsch B, Eze C, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Hofstetter K, et al. Among authors: tufman a. Strahlenther Onkol. 2024 Jul;200(7):614-623. doi: 10.1007/s00066-023-02175-6. Epub 2023 Nov 17. Strahlenther Onkol. 2024. PMID: 37975883 Free PMC article.
Corrigendum to "First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations" [Eur J Cancer 199 (2024) 113556].
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. Blasi M, et al. Among authors: tufman a. Eur J Cancer. 2024 Jul;205:114130. doi: 10.1016/j.ejca.2024.114130. Epub 2024 May 24. Eur J Cancer. 2024. PMID: 38789333 No abstract available.
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. Blasi M, et al. Among authors: tufman a. Eur J Cancer. 2024 Mar;199:113556. doi: 10.1016/j.ejca.2024.113556. Epub 2024 Jan 17. Eur J Cancer. 2024. PMID: 38271745 Free article.
129 results